Namvar Kiaie Joinsaditx Therapeutics, Inc.'s Board of Directors
August 25, 2020 at 08:00 am
Share
ADiTx Therapeutics, Inc. announced that it has appointed Namvar Kiaie to the Company’s Board of Directors, effective as of July 2, 2020. Aditxt’s Board now includes six members, including Mr. Kiaie, who is an independent director in accordance with the applicable rules of the Nasdaq Stock Market LLC. Mr. Kiaie will serve as chair of the Compensation
Committee. Mr. Kiaie has over 30 years of experience in the medical industry and has been associated with Abbott Diabetes Care since December 2005 in positions of increasing responsibility including Director of Engineering from 2005-2007; R&D Director from 2007-2010; and Senior Director of R&D from 2010-present. Currently he is leading the R&D organization responsible for the development of next generation biosensing technologies in Abbott Diabetes Care’s New Analyte Ventures. Prior to joining Abbott, Mr. Kiaie held executive positions within the medical device industry implementing programs from conception to production, including regulatory responsibilities.
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
ADITXT, INC. 
